Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
116,000 shares traded after hours
fyi
https://investor.anipharmaceuticals.com/news/news-details/2020/ANI-Pharmaceuticals-Schedules-Conference-Call-to-Discuss-Second-Quarter-2020-Financial-Results/default.aspx
so there is a independent investor relations now ?
according to june 2017 corporate presentation the pig pituitary glands from a leading pork producer in the U.S
https://www.anipharmaceuticals.com/presentations/ANI%20Investor%20Presentation%20June%202017.pdf
off topic...
this is frightening and needs to be corrected
https://www.nytimes.com/2020/03/11/business/economy/coronavirus-china-trump-drugs.html
perhaps instead of vilifying pharma washington needs to be working on solutions to correct this now
the only question i have is regarding Bretylium Tosylate , i dont see any doctor not abiding by acls guidelines to prescribe it. so unless the guidelines are updated, well if anyone can shed some light on it , it would be much appreciated
so moving forward with corti , assuming a launch date in july, 5 months of sales for 2020
per art "I've described Cortrophin Gel as a potential $200 million free cash flow opportunity for ANI. "
by the end of 2020 no debt
revenue estimate for 2021 600 million ? with 280 million ebitda
whats the market cap for a company like that
so a snap shot now verses 3 months ago is a percentage of the 72 million accounts receivable is now cash on hand ,plus 50 million 1st quarter revenue plus a 50 million acquisition which added value to the company
yes i know about that did what they spend not add value to the company
along with 62 million cash and 72 million accounts receivable
we have a current market cap of 460 million
with revenue Guidance for 2020 , 213 to 226 million
and ebitda 80 to 86 million
not counting corti
whats wrong with that picture
understood, but they dont necessarily have to retire the shares
you would think at some point the company would consider investing in its self by buying back some shares ,
fyi shortage of pindolol
"The FDA’s website, which lists shortfalls in supplies of medicines as they occur, now shows a shortage of the pindolol tablets."
https://www.yahoo.com/finance/news/indias-sun-pharma-flags-hypertension-084648853.html
audro has now doubled in less than one week with no news, they are anip's partners , i wonder whats going on ?
whats going on with Aduro BioTech the last couple days, jumped from $1.35 to the $1.80s
JTFM
is that you of the SDC board ?
looking at ani's products i dont remember seeing adderall before,
https://www.anipharmaceuticals.com/products_type.php?type=Prescription
could the be adding products without a announcement.... by my count we are up to 140 skus
if so we are up from 86 skus from december's corporate presentation
https://www.anipharmaceuticals.com/presentations/ANI%20Corporate%20Presentation%20December%202019%20Final.pdf
6 could be huge,
isnt Mallinckrodt trying to sue the government , i wonder how thats working out for them ...... ot jtfm what do think of sesn
if the drug is not in current ACLS guidelines, is it even going to be in demand
the company has a nice amount of cash, buy back some shares
the wellspring website has been updated
https://www.aniglobalsource.com/
sad read , but i wonder if teva would sell the rights to ani
https://www.yahoo.com/news/faced-drug-shortfall-doctors-scramble-121921081.html
good catch , i wonder when the other doses Concerta will be launched
will there be a launch today ?
"An option with a date certain launch for Aspirin/Dipyridamole ER capsules of no later than October 1, 2019. The option allows ANI to source the product from Amneal through March 1, 2021 or until ANI launches its own product, whichever date is earlier. If ANI elects to exercise the option to launch product supplied by Amneal it will owe a milestone payment of between $0 and $10 million depending on the number of generic products in the market at the time of launch. Currently this is a $120 million annual U.S. market with only one generic competitor, according to Iqvia/IMS Health."
http://www.anipharmaceuticals.com/aboutus_newsmedia_view.php?i=153
nice to hear vancocin oral should launch in july
i would like to see a share buy back , to counter some of this
spending $500 million to modernize the gel ?
hasnt anip already updated it ?
looking at the most recent corporate presentation
http://www.anipharmaceuticals.com/presentations/ANI%20Corporate%20Presentation%20March%202019.pdf
a new teva basket of 31 products was purchased march 8th 2019 for 2.5 million , i dont remember seeing a press release
total pipeline products now 103
new corporate presentation
https://www.anipharmaceuticals.com/presentations/ANI%20Corporate%20Presentation%20March%202019.pdf
noticed new Sr Director of contract sales, Russel Miller
101.00 dollars per share based on a very conservative guidance
what should the market cap be for a company that has 100 million EBITDA
whats up with ATRS volume ?
is it me or is the ani website down ?
weather for Wednesday in baudette
high -23
low -35
i hate to say this it shows my age but i think it was Red Skelton
it also makes a a company with a 500 million market cap, with a 100 million in cash